May 1, 2023 10:56 AM EDT
Financing
Pharma
Cell/Gene Tx

Mile­stone Mon­day for Im­mat­ics’ Bris­tol My­ers-al­lied cell ther­a­py and 2sev­en­ty bio’s No­vo-part­nered he­mo­phil­ia A work

Kyle LaHucik

Senior Reporter

No­vo Nordisk is pony­ing up $15 mil­lion as part of 2sev­en­ty bio’s work on a pre­clin­i­cal gene ther­a­py can­di­date for he­mo­phil­ia A. Sep­a­rate­ly, Bris­tol My­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times